awmsg logo



umeclidinium/vilanterol (as trifenatate) (Anoro® Ellipta®)


Reference No. 1038

Publication date:
11/03/2015


Appraisal information

umeclidinium/vilanterol (as trifenatate) (Anoro® Ellipta®) 55 micrograms/22 micrograms inhalation powder


Company: GlaxoSmithKline
BNF category: Respiratory system
NMG meeting date: 07/01/2015
AWMSG meeting date: 11/02/2015
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0215
Ministerial ratification: 10/03/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Umeclidinium/vilanterol (as trifenatate) (Anoro® Ellipta®) is recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download